ArticlePLoS neglected tropical diseases2023
Diagnostic capacities and treatment practices on implantation mycoses: Results from the 2022 WHO global online survey.
Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026Article
- Mycetoma.PLoS neglected tropical diseases · 2026Review
- Implantation mycoses: A nationwide survey on diagnostic and treatment modalities in Nepal.PLoS neglected tropical diseases · 2026Article
- Sandalwood Sesquiterpene (Molecules (Basel, Switzerland) · 2025Article
- Concurrent chromoblastomycosis and eumycetoma: a unique case of dual neglected tropical fungal diseases in Asia.PLoS neglected tropical diseases · 2025Article
- Chromoblastomycosis: a case series from Sumba, eastern Indonesia.Clinical and experimental dermatology · 2025Article
- South-East Asia regional neglected tropical disease framework: improving control of mycetoma, chromoblastomycosis, and sporotrichosis.The Lancet regional health. Southeast Asia · 2025Review
- Mycetoma in Somalia: an updated literature review.Annals of medicine and surgery (2012) · 2025Review
- Towards enhanced control of mycetoma: a roadmap to achieve the UN's sustainable development goals by 2030.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2024Article
- A global chromoblastomycosis strategy and development of the global chromoblastomycosis working group.PLoS neglected tropical diseases · 2024Article
- An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.Clinical microbiology reviews · 2024Review
- Social determinants of health as drivers of fungal disease.EClinicalMedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Between January and March 2022, WHO conducted a global online survey to collect data on diagnostic capacities and treatment practices in different settings for four implantation mycoses: eumycetoma, actinomycetoma, cutaneous sporotrichosis and chromoblastomycosis. The survey investigated the type of diagnostic methods available in countries at various health system levels (tertiary, secondary, primary level) and the medicines used to treat implantation mycoses, with a view to understanding the level of drug repurposing for treatment of these diseases. 142 respondents from 47 countries, including all continents, contributed data: 60% were from middle-income countries, with 59% working at the tertiary level of the health system and 30% at the secondary level. The results presented in this article provide information on the current diagnostic capacity and treatment trends for both pharmacological and non-pharmacological interventions. In addition, the survey provides insight on refractory case rates, as well as other challenges, such as availability and affordability of medicines, especially in middle-income countries. Although the study has limitations, the survey-collected data confirms that drug repurposing is occurring for all four surveyed implantation mycoses. The implementation of an openly accessible global and/or a national treatment registry for implantation mycoses could contribute to address the gaps in epidemiological information and collect valuable observational data to inform treatment guidelines and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.